A patent review on hypoxia-inducible factor (HIF) modulators (2021–2023)

References

• Olenyuk BZ, Zhang G, Klco JM, et al. Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci USA. 2004;101(48):16768–16773. doi: 10.1073/pnas.0407617101
   PubMed Web of Science ®Google Scholar
• Li Z, You Q, Zhang X. Small-molecule modulators of the hypoxia-inducible factor pathway: development and therapeutic applications. J Med Chem. 2019;62(12):5725–5749. doi: 10.1021/acs.jmedchem.8b01596
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xing C, Deng Y, et al. HIF-1α signaling: essential roles in tumorigenesis and implications in targeted therapies. Genes Dis. 2024;11(1):234–251. doi: 10.1016/j.gendis.2023.02.039
   PubMed Web of Science ®Google Scholar
• Ahmed R, Ornstein MC. Targeting HIF-2 alpha in renal cell carcinoma. Curr Treat Options Oncol. 2023;24(9):1183–1198. doi: 10.1007/s11864-023-01106-y
   PubMed Web of Science ®Google Scholar
• Zhang P, Yao Q, Lu L, et al. Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia. Cell Rep. 2014;6(6):1110–1121. doi: 10.1016/j.celrep.2014.02.011
   PubMed Web of Science ®Google Scholar
• Qingdong K, Max C. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol. 2006;70(5):1469. doi: 10.1124/mol.106.027029
   PubMed Web of Science ®Google Scholar
• Hu C, Wang L, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1α (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol. 2003;23(24):9361–9374. doi: 10.1128/MCB.23.24.9361-9374.2003
   PubMed Web of Science ®Google Scholar
• Nordgren IK, Tavassoli A. Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor. Chem Soc Rev. 2011;40(8):4307–4317. doi: 10.1039/c1cs15032d
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H, et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464–468. doi: 10.1126/science.1059817
   PubMed Web of Science ®Google Scholar
• Yamashita K, Discher DJ, Hu J, et al. Molecular regulation of the endothelin-1 gene by hypoxia: contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300/CBP. J Biol Chem. 2001;276(16):12645–12653. doi: 10.1074/jbc.M011344200
   PubMed Web of Science ®Google Scholar
• Lando D, Peet DJ, Whelan DA, et al. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science. 2002;295(5556):858–861. doi: 10.1126/science.1068592
   PubMed Web of Science ®Google Scholar
• Gu Y, Moran SM, Hogenesch JB, et al. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr. 1998;7:205–213.
   PubMed Web of Science ®Google Scholar
• Hara S, Hamada J, Kobayashi C, et al. Expression and characterization of hypoxia-inducible factor (HIF)-3α in human kidney: suppression of HIF-mediated gene expression by HIF-3α. Biochem Biophys Res Commun. 2001;287(4):808–813. doi: 10.1006/bbrc.2001.5659
   PubMed Web of Science ®Google Scholar
• Tanaka T, Wiesener M, Bernhardt W, et al. The human HIF (hypoxia-inducible factor)-3α gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem J. 2009;424(1):143–151. doi: 10.1042/BJ20090120
   PubMedGoogle Scholar
• Smith TG, Talbot NP. Prolyl hydroxylases and therapeutics. Antioxidants & Redox Signaling. 2009;12(4):431–433. doi: 10.1089/ars.2009.2901
   Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian Y, et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468–472. doi: 10.1126/science.1059796
   PubMed Web of Science ®Google Scholar
• Lee JH, Han YS, Yoon YM, et al. Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis. Oncogene. 2017;36(47):6555–6567. doi: 10.1038/onc.2017.263
   PubMed Web of Science ®Google Scholar
• Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal Physiol. 2006;291(2):F271–F281. doi: 10.1152/ajprenal.00071.2006
   PubMed Web of Science ®Google Scholar
• Volkova YL, Pickel C, Jucht AE, et al. The asparagine hydroxylase FIH: a unique oxygen sensor. Antioxid Redox Signal. 2022;37(13–15):913–935. doi: 10.1089/ars.2022.0003
   PubMed Web of Science ®Google Scholar
• Voit RA, Sankaran VG. Stabilizing HIF to ameliorate anemia. Cell. 2020;180(1):6. doi: 10.1016/j.cell.2019.12.010
   PubMed Web of Science ®Google Scholar
• Wu D, Potluri N, Lu J, et al. Structural integration in hypoxia-inducible factors. Nature. 2015;524(7565):303–308. doi: 10.1038/nature14883
   PubMed Web of Science ®Google Scholar
• Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664–3671. doi: 10.1172/JCI67230
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Kaelin WG. Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat Med. 2020;26(10):1519–1530. doi: 10.1038/s41591-020-1093-z
   PubMed Web of Science ®Google Scholar
• Semenza GL. Regulation of erythropoiesis by the hypoxia-inducible factor pathway: effects of genetic and pharmacological perturbations. Annu Rev Med. 2023;74(1):307–319. doi: 10.1146/annurev-med-042921-102602
   PubMedGoogle Scholar
• Jiang W, Abdulkadir S, Zhao X, et al. Inhibition of hypoxia-inducible transcription factor (HIF-1α) signaling with sulfonyl-γ-AApeptide helices. J Am Chem Soc. 2023;145(36):20009–20020. doi: 10.1021/jacs.3c06694
   PubMed Web of Science ®Google Scholar
• Li H, Liu Y, Xue Z, et al. Adamantanilinederivatives target ATP5B to inhibit translation of hypoxia inducible factor-1 α. Adv Sci (Weinh). 2023;10(25):e2301071. doi: 10.1002/advs.202301071
   PubMedGoogle Scholar
• Fudan University. Benzoisoxazole-3-formamides and their synthesis and application. CN115677608. 2023.
   Google Scholar
• Xue Z, Li H, Xie W, et al. Benzo[d]isoxazole derivatives as hypoxia-inducible factor (HIF)-1α inhibitors. ACS Med Chem Lett. 2022;13(12):1864–1869. doi: 10.1021/acsmedchemlett.2c00308
   PubMed Web of Science ®Google Scholar
• Scheuermann TH, Li Q, Ma H, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol. 2013;9(4):271–276. doi: 10.1038/nchembio.1185
   PubMed Web of Science ®Google Scholar
• Cho H, Du X, Rizzi JP, et al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 2016;539(7627):107–111. doi: 10.1038/nature19795
   PubMed Web of Science ®Google Scholar
• Deeks ED. Belzutifan: first approval. Drugs. 2021;81(16):1921–1927. doi: 10.1007/s40265-021-01606-x
   PubMed Web of Science ®Google Scholar
• Ren X, Diao X, Zhuang J, et al. Structural basis for the allosteric inhibition of hypoxia-inducible factor 2 by belzutifan. Mol Pharmacol. 2022;102(6):240–247. doi: 10.1124/molpharm.122.000525
   Google Scholar
• Merck Patent GmbH and Ryvu Therapeutics S.A. Condensed thiophene derivatives as hypoxia inducible factor (HIF) inhibitors and their preparation. WO2021105069. 2021.
   Google Scholar
• Buchstaller HP, Sala-Hojman A, Leiendecker M, et al. Discovery of cycloalkyl[c]thiophenes as novel scaffolds for hypoxia-inducible factor-2α inhibitors. J Med Chem. 2023;66(13):8666–8686. doi: 10.1021/acs.jmedchem.3c00332
   PubMed Web of Science ®Google Scholar
• Beijing Konruns Pharmaceutical Co. Ltd. Preparation of piperazine containing bifunctional compounds and application as antitumor agent. CN116789636. 2023.
   Google Scholar
• Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nat Chem Biol. 2019;15(10):937–944. doi: 10.1038/s41589-019-0362-y
   PubMed Web of Science ®Google Scholar
• Bekes M, Langley DR, Crew CM. PROTAC targeted protein degrader: the past is prologue. Nat Rev Drug Discov. 2022;21:181–200. doi: 10.1038/s41573-021-00371-6
   PubMed Web of Science ®Google Scholar
• Zhejiang University and Jinhua Institute of Zhejiang University. Preparation of 7-difluoromethyl-5-arylpyrazolopyrimidine derivatives as HIF-2α inhibitors. CN116836168. 2023.
   Google Scholar
• Schofield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun. 2005;338(1):617–626. doi: 10.1016/j.bbrc.2005.08.111
   PubMed Web of Science ®Google Scholar
• Appelhoff RJ, Tian Y-M, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem. 2004;279(37):38458–38465. doi: 10.1074/jbc.M406026200
   PubMed Web of Science ®Google Scholar
• Berra E, Benizri E, Ginouvès A, et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 in normoxia. The EMBO Journal. 2003;22(16):4082–4090. doi: 10.1093/emboj/cdg392
   PubMed Web of Science ®Google Scholar
• Chowdhury R, McDonough MA, Mecinović J, et al. Structural basis for binding of hypoxia-inducible factor to the oxygen-sensing prolyl hydroxylases. Structure. 2009;17(7):981–989. doi: 10.1016/j.str.2009.06.002
   PubMed Web of Science ®Google Scholar
• Dhillon S. Daprodustat: first approval. Drugs. 2020;80:1491–1497. doi: 10.1007/s40265-020-01384-y
   PubMedGoogle Scholar
• Dhillon S. Desidustat: First approval. Drugs. 2022;82:1207–1212. doi: 10.1007/s40265-022-01744-w
   PubMedGoogle Scholar
• Markham A. Enarodustat: First approval. Drugs. 2021;81:169–174. doi: 10.1007/s40265-020-01444-3
   PubMedGoogle Scholar
• Beck H, Jeske M, Thede K, et al. Discovery of molidustat (BAY 85‐3934): A small‐molecule oral HIF‐prolyl hydroxylase (HIF‐PH) inhibitor for the treatment of renal anemia. ChemMedchem. 2018;13(10):988–1003. doi: 10.1002/cmdc.201700783
   PubMed Web of Science ®Google Scholar
• Figg JW, Ma M, Chowdhury R, et al. Structural basis of prolyl hydroxylase domain inhibition by molidustat. ChemMedchem. 2021;16(13):2082–2088. doi: 10.1002/cmdc.202100133
   PubMed Web of Science ®Google Scholar
• Dhillon S. Roxadustat: First global approval. Drugs. 2019;79:563–572. doi: 10.1007/s40265-019-01077-1
   PubMed Web of Science ®Google Scholar
• Markham A. Vadadustat: first approval. Drugs. 2020;80:1365–1371. doi: 10.1007/s40265-020-01383-z
   PubMedGoogle Scholar
• McDonough MA, Li V, Flashman E, et al. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA. 2006;103(26):9814–9819. doi: 10.1073/pnas.0601283103
   PubMed Web of Science ®Google Scholar
• Lei Y, Hu T, Wu X, et al. Affinity-based fluorescence polarization assay for high-throughput screening of prolyl hydroxylase 2 inhibitors. ACS Med Chem Lett. 2015;6(12):1236–1240. doi: 10.1021/acsmedchemlett.5b00394
   PubMed Web of Science ®Google Scholar
• Jennifer LA, Kevin JD, David FA, et al. Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor–prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther. 2017;363(3):336. doi: 10.1124/jpet.117.242503
   PubMed Web of Science ®Google Scholar
• Yeh T-L, Leissing Thomas M, Abboud MI, et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem Sci. 2017;8(11):7651–7668. doi: 10.1039/C7SC02103H
   PubMed Web of Science ®Google Scholar
• Insilico Medicine IP Limited. 1,7-naphthyridine derivatives as PHD inhibitors and their preparation. WO2023072246. 2023.
   Google Scholar
• Xu J, Ding X, Fu Y, et al. Discovery of novel and potent prolyl hydroxylase domain-containing protein (PHD) inhibitors for the treatment of anemia. J Med Chem. 2024;67(2):1393–1405. doi: 10.1021/acs.jmedchem.3c01932
   PubMed Web of Science ®Google Scholar
• Suzhong Pharmaceutical Group Co. Ltd. And Jiangsu Suzhong Pharmaceutical Research Institute Co. Ltd. Preparation of pyridotriazole compounds as prolyl hydroxylase inhibitor. CN116496269. 2023.
   Google Scholar
• China Pharmaceutical University. Preparation of cyclic substituted acetylpyridinylglycine derivatives for the treatment of anemia or ischemic diseases. CN116514710. 2023.
   Google Scholar
• Dann CE, Bruick RK, Deisenhofer J. Structure of factor-inhibiting hypoxia-inducible factor 1: an asparaginyl hydroxylase involved in the hypoxic response pathway. Proc Natl Acad Sci USA. 2002;99(24):15351–15356. doi: 10.1073/pnas.202614999
   PubMed Web of Science ®Google Scholar
• Wu Y, Li Z, McDonough MA, et al. Inhibition of the oxygen-sensing asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor: a potential hypoxia response modulating strategy. J Med Chem. 2021;64(11):7189–7209. doi: 10.1021/acs.jmedchem.1c00415
   PubMed Web of Science ®Google Scholar
• McDonough MA, McNeill LA, Tilliet M, et al. Selective inhibition of factor inhibiting hypoxia-inducible factor. J Am Chem Soc. 2005;127(21):7680–7681. doi: 10.1021/ja050841b
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University. Preparation of N-oxalyl-D-phenylalanine compounds and their ester prodrug and its application. CN115806501. 2023.
   Google Scholar
• Diehl CJ, Ciulli A. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Chem Soc Rev. 2022;51(19):8216–8257. doi: 10.1039/D2CS00387B
   PubMed Web of Science ®Google Scholar
• Qiu S, Jia Y, Tang J, et al. Von Hippel-Lindau (VHL) protein antagonist, VH298, promotes functional activities of tendon-derived stem cells and accelerates healing of entheses in rats by inhibiting ubiquitination of hydroxy-HIF-1α. Biochem Biophys Res Commun. 2018;505(4):1063–1069. doi: 10.1016/j.bbrc.2018.09.172
   PubMed Web of Science ®Google Scholar
• Qiu S, Jia Y, Sun Y, et al. Von Hippel-Lindau (VHL) protein antagonist VH298 improves wound healing in streptozotocin-induced hyperglycaemic rats by activating hypoxia-inducible factor- (HIF-) 1 signalling. J Diabetes Res. 2019;2019:1897174. doi: 10.1155/2019/1897174
   PubMed Web of Science ®Google Scholar
• Xue X, Kang J, Yang X, et al. An efficient strategy for digging protein-protein interactions for rational drug design - a case study with HIF-1α/VHL. Eur J Med Chem. 2022;227:113871. doi: 10.1016/j.ejmech.2021.113871
   PubMed Web of Science ®Google Scholar
• Genentech, Inc. Preparation of 1-[2-(4-cyclopropyl-1H-1,2,3-triazol-1-yl)acetyl]-4-hydroxy-N-benzylpyrrolidine-2-carboxamide derivatives as VHL inhibitors for treating anemia and cancer. WO2022103411. 2022.
   Google Scholar
• Genentech, Inc. Preparation of pyrrolidine derivatives and methods of use. WO2022115879. 2022.
   Google Scholar
• Wu D, Su X, Lu J, et al. Bidirectional modulation of HIF-2 activity through chemical ligands. Nat Chem Biol. 2019;15(4):367–376. doi: 10.1038/s41589-019-0234-5
   PubMed Web of Science ®Google Scholar
• Yu Y, Yu Q, Zhang X. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma. Drug Discovery Today. 2019;24(12):2332–2340. doi: 10.1016/j.drudis.2019.09.008
   PubMed Web of Science ®Google Scholar
• Yu Y, Yu Q, Liu S, et al. Insight into the binding mode of HIF-2 agonists through molecular dynamic simulations and biological validation. Eur J Med Chem. 2021;211:112999. doi: 10.1016/j.ejmech.2020.112999
   PubMed Web of Science ®Google Scholar
• Nanjing University of Chinese Medicine and Shandong University. Preparation method of benzoisothiazole and benzothiophene, and its application in preventing and treating renal failure, hypertension and coronary heart disease. CN113264900. 2021.
   Google Scholar
• Song W, Zhuang J, Zhang N, et al. SAR study of 1,2-benzisothiazole dioxide compounds that agonize HIF-2 stabilization and EPO production. Bioorg Med Chem. 2023;77:117041. doi: 10.1016/j.bmc.2022.117041
   PubMed Web of Science ®Google Scholar
• China Pharmaceutical University. Preparation of benzoisothiazole-benzamide compounds for the treatment of ischemic diseases. CN115872947. 2023.
   Google Scholar
• China Pharmaceutical University. Benzoisothiazole hypoxia inducible factor 2 agonist compound or its pharmaceutically acceptable salt, its preparation method and application. WO2022242462. 2022.
   Google Scholar
• Yu Y, Yang F, Yu Q, et al. Discovery of a potent and orally bioavailable hypoxia-inducible factor 2α (HIF-2α) agonist and its synergistic therapy with prolyl hydroxylase inhibitors for the treatment of renal anemia. J Med Chem. 2021;64(23):17384–17402. doi: 10.1021/acs.jmedchem.1c01479
   PubMed Web of Science ®Google Scholar
• Zhejiang University. Application of aromatic heterocyclic formamide compounds. CN116236478. 2023.
   Google Scholar
• Shandong University and Jinan Chengcheng Biotechnology Co. Ltd. Application of active molecules regulating hypoxia-inducible factor 3α in treatment of diseases. CN116407635. 2023.
   Google Scholar
• Diao X, Ye F, Zhang M, et al. Identification of oleoylethanolamide as an endogenous ligand for HIF-3α. Nat Commun. 2022;13(1):2529. doi: 10.1038/s41467-022-30338-z
   PubMed Web of Science ®Google Scholar
• Choudhry H, Harris AL. Advances in hypoxia-inducible factor biology. Cell Metab. 2018;27(2):281–298. doi: 10.1016/j.cmet.2017.10.005
   PubMed Web of Science ®Google Scholar
• Wu Q, You L, Nepovimova E, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15(1):77. doi: 10.1186/s13045-022-01292-6
   PubMed Web of Science ®Google Scholar
• Strowitzki MJ, Cummins EP, Taylor CT. Protein hydroxylation by hypoxia-inducible factor (HIF) hydroxylases: unique or ubiquitous? Cells. 2019;8(5):384. doi: 10.3390/cells8050384
   PubMed Web of Science ®Google Scholar
• Oh ET, Kim JW, Kim JM, et al. NQO1 inhibits proteasome-mediated degradation of HIF-1α. Nat Commun. 2016;7(1):13593. doi: 10.1038/ncomms13593
   PubMedGoogle Scholar
• Wang F, Chen L, Kong D, et al. Canonical wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1α transcriptional complex. Hepatology. 2024;79(3):606–623. doi: 10.1097/HEP.0000000000000569
   PubMed Web of Science ®Google Scholar
• Victor RG, Galina YM, Adelina IS, et al. Thrombotic risk in congenital erythrocytosis due to up-regulated hypoxia sensing is not associated with elevated hematocrit. Haematologica. 2020;105(3):e87–e90. doi: 10.3324/haematol.2019.216267
   PubMed Web of Science ®Google Scholar
• Chen D, Niu Y, Liu F, et al. Safety of HIF prolyl hydroxylase inhibitors for anemia in dialysis patients: a systematic review and network meta-analysis. Front Pharmacol. 2023;14:1163908. doi: 10.3389/fphar.2023.1163908
   PubMed Web of Science ®Google Scholar
• Chen H, Cheng Q, Wang J, et al. Long‐term efficacy and safety of hypoxia‐inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta‐analysis including 13,146 patients. J Clin Pharm Ther. 2021;46(4):999–1009. doi: 10.1111/jcpt.13385
   PubMed Web of Science ®Google Scholar
• Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for renal cell carcinoma in von Hippel–Lindau disease. N Engl J Med. 2021;385(22):2036–2046. doi: 10.1056/NEJMoa2103425
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature Med. 2021;27(5):802–805. doi: 10.1038/s41591-021-01324-7
   PubMed Web of Science ®Google Scholar
• Choueiri TK, McDermott DF, Merchan J, et al. Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. Lancet Oncol. 2023;24(5):553–562. doi: 10.1016/S1470-2045(23)00097-9
   PubMed Web of Science ®Google Scholar
• Duan C. Hypoxia-inducible factor 3 biology: complexities and emerging themes. Am J Physiol Cell Physiol. 2016;310(4):c260–C269. doi: 10.1152/ajpcell.00315.2015
   PubMed Web of Science ®Google Scholar
• Glaspy J, Garail NY, Locantore-Ford P, et al. Open-label, phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies. American J Hematol. 2023;98(5):703–711. doi: 10.1002/ajh.26865
   PubMed Web of Science ®Google Scholar
• Henry DH, Glaspy J, Harrup R, et al. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022;97(2):174–184. doi: 10.1002/ajh.26397
   PubMed Web of Science ®Google Scholar
• Su K, Li Z, Yu Y, et al. The prolyl hydroxylase inhibitor roxadustat: paradigm in drug discovery and prospects for clinical application beyond anemia. Drug Discov Today. 2020;25(7):1262–1269. doi: 10.1016/j.drudis.2020.04.017
   PubMed Web of Science ®Google Scholar
• Kamihara J, Hamiton KV, Pollard JA, et al. Belzutifan, a potent hif2α inhibitor, in the pacak–zhuang syndrome. N Engl J Med. 2021;385(22):2059–2065. doi: 10.1056/NEJMoa2110051
   PubMed Web of Science ®Google Scholar